When was Pleryon Therapeutics founded?

Pleryon Therapeutics was founded in 2017 and raised its 1st funding round 5 years after it was founded.

Where is Pleryon Therapeutics located?

Pleryon Therapeutics is headquartered in Shenzhen, China.

How many employees does Pleryon Therapeutics have?

As of Jun 30, 2026, the latest employee count at Pleryon Therapeutics is 7.

Is Pleryon Therapeutics a funded company?

Pleryon Therapeutics is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2022.

When was the latest funding round of Pleryon Therapeutics?

Pleryon Therapeutics' latest funding was a $***** Series A round on Aug 18, 2025, with participation from 1 investor. Its primary sector is Ophthalmology. In China, the Ophthalmology sector has seen $31M in funding in 2026 to date.

Where does Pleryon Therapeutics rank among its competitors?

Pleryon Therapeutics ranks 1856th amongst 2652 active competitors, of which 904 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Pleryon Therapeutics?

Pleryon Therapeutics' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Pleryon Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Pleryon Therapeutics is a series A company based in Shenzhen (China), founded in 2017. It operates as a Developer of drug delivery and biomaterials technologies. Pleryon Therapeutics has raised an undisclosed amount in funding from Efung Capital. The company has 2652 active competitors, including 904 funded and 678 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Pleryon Therapeutics is a spin-off of the Hong Kong University of Science and Technology. They are developing drug delivery and biomaterials technologies. The company has developed their proprietary long-term protein release hydrogel (KA-P hydrogel) technology. Using the platform they are reformulating drugs for treating various diseases including age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO).

Key Metrics

Founded Year

2017

Location

Shenzhen, China

Stage

Series A

Latest Funding Round

Series A, Aug 18, 2025, $*****

Investors

Efung Capital

Ranked

1856^th among 2652 active competitors

Employee Count

7 as on Jun 30, 2026

Similar Companies

Viridian Therapeutics & 288 more

View Pleryon Therapeutics' full profile

Pleryon Therapeutics has raised funding over 2 rounds. Its first funding round was on 2022. Its latest funding round was a Series A round on Aug 18, 2025 for $*****. 1 investor participated in its latest round. Pleryon Therapeutics has 1 institutional investor.

Here is the list of recent funding rounds of Pleryon Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 18, 2025	9386399	Series A	7246497	4146567	3616872	5900269
2022	2822	Seed	1384	4064	2959	3436

Access funding benchmarks and valuations. Sign up today!

View details of Pleryon Therapeutics's funding rounds and investors

Pleryon Therapeutics' employee count trend

Pleryon Therapeutics has 7 employees as of Jun 26. Here is Pleryon Therapeutics's employee count trend over the years:

Employee count trend for Pleryon Therapeutics

Uncover Pleryon Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Pleryon Therapeutics include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Pleryon Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Livzon Pharmaceutical & 5 others	71/100
10th	Celularity 2016, Warren (United States), Public	Developer of allogeneic cell therapies to treat multiple diseases	$290M	Celgene, Dreyfus Family Office & 8 others	71/100
1856th	Pleryon Therapeutics 2017, Shenzhen (China), Series A	Developer of drug delivery and biomaterials technologies	-	Efung Capital	26/100